The estimated Net Worth of Richard Eberly is at least $1.05 million dollars as of 15 March 2022. Mr Eberly owns over 377,145 units of Chembio Diagnostics stock worth over $124,123 and over the last 21 years he sold CEMI stock worth over $374,126. In addition, he makes $556,033 as Pres et CEO & Director at Chembio Diagnostics.
Mr has made over 7 trades of the Chembio Diagnostics stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 377,145 units of CEMI stock worth $173,487 on 15 March 2022.
The largest trade he's ever made was exercising 377,145 units of Chembio Diagnostics stock on 15 March 2022 worth over $173,487. On average, Mr trades about 11,241 units every 75 days since 2003. As of 15 March 2022 he still owns at least 269,833 units of Chembio Diagnostics stock.
You can see the complete history of Mr Eberly stock trades at the bottom of the page.
Richard L. Eberly is the Pres, CEO & Director at Chembio Diagnostics.
As the Pres et CEO & Director of Chembio Diagnostics, the total compensation of Mr Eberly at Chembio Diagnostics is $556,033. There are 1 executives at Chembio Diagnostics getting paid more, with Javan Esfandiari having the highest compensation of $557,521.
Mr Eberly is 60, he's been the Pres et CEO & Director of Chembio Diagnostics since . There are 3 older and 4 younger executives at Chembio Diagnostics. The oldest executive at Chembio Diagnostics Inc. is Mary Polan, 76, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.
Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert et Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Chembio Diagnostics executives and other stock owners filed with the SEC include: